COLL
NASDAQ
US
Collegium Pharmaceutical, Inc. - Common Stock
$32.31
▼ $-0.94
(-2.83%)
Vol 584K
11
Quality Score
ok
Deep Check
2/5
ok
Rev ✓
NI ✓
>IPO ✗
Mkt Cap
$1.5B
P/E
25.0
ROE
24.1%
Margin
7.7%
D/E
294.07
Beta
0.65
52W
$23–$50
Wall Street Consensus
12 analysts · Apr 20263
Strong Buy
7
Buy
2
Hold
0
Sell
0
Strong Sell
83.3%
Buy Rating
Price Chart
Similar Stocks
Earnings
Beat rate: 75.0%
Next Report
May 06, 2026
EPS Estimate: $1.64
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $1.64 | — | — |
| Dec 2025 | $2.37 | $2.04 | $-0.33 |
| Sep 2025 | $2.08 | $2.25 | +$0.17 |
| Jun 2025 | $1.65 | $1.68 | +$0.03 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Revenue | — | $181.9M | $177.8M | $188.0M | $209.4M | $205.4M |
| Net Income | — | $12.5M | $2.4M | $12.0M | $31.5M | $17.0M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | 15.6% | 15.6% | 15.6% | 15.6% | 24.1% | 24.1% |
| P/E (TTM) | 26.20 | 32.67 | 30.74 | 31.27 | 25.08 | 25.04 |
| Net Margin | 6.4% | 5.1% | 5.1% | 5.1% | 7.7% | 7.7% |
| Gross Margin | 57.6% | 56.7% | 56.7% | 56.7% | 57.2% | 57.2% |
| D/E Ratio | 354.39 | 354.39 | 354.39 | 354.39 | 294.07 | 294.07 |
| Current Ratio | 1.18 | 1.18 | 1.18 | 1.18 | 1.36 | 1.36 |
Key Ratios
ROA (TTM)
3.6%
P/S (TTM)
1.93
P/B
4.0
EPS (TTM)
$1.49
CF/Share
$4.22
Rev Growth 3Y
+31.6%
52W High
$50.01
52W Low
$23.23
$23.23
52-Week Range
$50.01
Financial Health
Free Cash Flow
$122.4M
Net Debt
$583.6M
Cash
$231.3M
Total Debt
$814.9M
As of Dec 31, 2025
How does COLL compare to Pharmaceuticals peers?
Peer group: Micro-cap Pharmaceuticals (All) · 171 companies
COLL valuation vs Pharmaceuticals peers
P/E ratio
25.0
▲
12%
above
peers
(22.4)
vs Peers
vs Industry
Undervalued
P/S ratio
1.9
▼
61%
below
peers
(5.0)
vs Peers
vs Industry
Undervalued
P/B ratio
4.0
▲
90%
above
peers
(2.1)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(2.0%)
vs Peers
vs Industry
Low yield
COLL profitability vs Pharmaceuticals peers
ROE
24.1%
▲
144%
above
peers
(-54.3%)
vs Peers
vs Industry
Top tier
Net margin
7.7%
▲
116%
above
peers
(-47.4%)
vs Peers
vs Industry
Below avg
Gross margin
57.2%
▼
16%
below
peers
(68.3%)
vs Peers
vs Industry
Weak
ROA
3.6%
▲
110%
above
peers
(-37.4%)
vs Peers
vs Industry
Top tier
COLL financial health vs Pharmaceuticals peers
D/E ratio
294.1
▲
18995%
above
peers
(1.5)
vs Peers
vs Industry
High debt
Current ratio
1.4
▼
60%
below
peers
(3.4)
vs Peers
vs Industry
Low liquidity
Beta
0.7
▼
31%
below
peers
(0.9)
vs Peers
vs Industry
More volatile
COLL fundamentals radar
COLL
Peer median
Industry
COLL profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
COLL vs peers: key metrics
Related Signals
Insider Activity
NeutralBuys
0
Sells
0
DIETER DAVID
General Counsel · Mar 18
13976 shs
DIETER DAVID
General Counsel · Mar 09
6224 shs
DREYER SCOTT
Officer · Mar 03
49976 shs
KARNANI VIKRAM
Chief Executive Officer · Feb 10
111795 shs
DREYER SCOTT
Officer · Feb 10
49725 shs
SMITH THOMAS BRAIN M.D.
Officer · Feb 10
37042 shs
TUPPER COLLEEN
Chief Financial Officer · Feb 10
59155 shs
DIETER DAVID
General Counsel · Feb 10
31199 shs
Last 90 days
Top Holders
Top 5: 38.89%Blackrock Inc.
16.06%
$165.4M
Vanguard Group Inc
7.11%
$73.2M
Eventide Asset Management L…
5.91%
$60.9M
Renaissance Technologies, L…
5.09%
$52.5M
Fuller & Thaler Asset Manag…
4.72%
$48.7M
As of Dec 31, 2025